75146837

CH \$40,00

TRADEMARK ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type	
OXFORD FINANCE		104/06/2011	BANKING	
CORPORATION			ASSOCIATION: DELAWARE	

RECEIVING PARTY DATA

Name:	TITAN PHARMACEUTICALS, INC.
Street Address:	400 OYSTER POINT BLVD., SUITE 505
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 1

Property Type	Number	Word Mark
Serial Number:	75146837	SPHERAMINE

CORRESPONDENCE DATA

Fax Number: (858)638-5016

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 8586771416

Email: lisa.ortiz@dlapiper.com

Correspondent Name: DLA Piper LLP (US)

Address Line 1: 4365 Executive Drive, Suite 1100

Address Line 2: Attn: Lisa A. Ortiz

Address Line 4: San Diego, CALIFORNIA 92121

ATTORNEY DOCKET NUMBER:	368986-000014
NAME OF SUBMITTER:	TROY ZANDER
Signature:	/S/ TROY ZANDER

TRADEMARK REEL: 004516 FRAME: 0468

900188628

Date:	04/06/2011
Total Attachments: 3 source=Titan - Release#page1.tif source=Titan - Release#page2.tif source=Titan - Release#page3.tif	

TRADEMARK REEL: 004516 FRAME: 0469

REASSIGNMENT AND RELEASE OF SECURITY INTEREST

This Reassignment and Release of Security Interest is executed as of April $\underline{\mathcal{U}}$, 2011 by OXFORD FINANCE CORPORATION ("Assignor") for the benefit of TITAN PHARMACEUTICALS, INC., a Delaware corporation ("Assignee").

RECITALS

- A. WHEREAS, Assignee assigned certain interests in the intellectual property described on Exhibit A and Exhibit B (the "IP") to the Assignor under that certain Intellectual Property Security Agreement dated as of December 23, 2009, as amended and restated by that certain Amended and Restated Intellectual Property Security Agreement dated as of September 27, 2010, recorded with the U.S. Patent and Trademark Office; and
- B. WHEREAS, the Assignor wishes to release and reassign all interest that the Assignor may have in the IP.

AGREEMENT

NOW, THEREFORE, the Assignor agrees that it releases its security interest in the IP and reassigns to Assignee, without warranty or recourse, all interest of the Assignor in the IP.

ASSIGNOR:

Address of ASSIGNOR:

OXFORD FINANCE CORPORATION

133 North Fairfax Street Alexandria, VA 22314

By:

Title:

ice President & General Counsel

-1-

EXHIBIT A

<u>Patents</u>

1. Use of gallium to treat biofilm-associated infections 11700289 1/30/07 2. Implantable polymeric device for sustained release of buprenorphine 10453377 6/2/03 3. Combination of chemotherapeutic drugs for increasing antitumor activity 10521548 8/22/05 4. Implantable polymeric device for sustained release of dopamine agonist 10815481 3/31/04 4. Implantable polymeric device for sustained release of 10815481 3/31/04 4. Implantable polymeric device for sustained release of 10856178 5/27/04 5. Implantable polymeric device for sustained release of 10856178 12/17/04 7. Use of gallium to treat inflammatory arthritis 11015172 12/17/04 7. Use of pigmented retinal epithelial cells for creation of an immune privilege site 11497914 8/1/06 8. Methods of treating schizophrenia 11497914 8/1/06 9. Treatment and prevention of adverse liver conditions 11594582 11/7/06 using gallium 10. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst 11805608 5/23/07 buprenorphine with minimal initial burst 12. Implantable polymeric device for sustained release of 12119334 5/12/08 dopamine agonist 13. Method for gene transfer to the central nervous 6210664 4/3/01 system	<u>Description</u>	Pat./Appl.Number	File Date
buprenorphine 3. Combination of chemotherapeutic drugs for increasing antitumor activity 4. Implantable polymeric device for sustained release of dopamine agonist 5. Implantable polymeric device for sustained release of nalmefene 6. Use of gallium to treat inflammatory arthritis 7. Use of pigmented retinal epithelial cells for creation of an immune privilege site 8. Methods of treating schizophrenia 8. Methods of treating schizophrenia 9. Treatment and prevention of adverse liver conditions using gallium 10. Implantable polymeric device for sustained release of buprenorphine 11. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst 12. Implantable polymeric device for sustained release of dopamine agonist 13. Method for gene transfer to the central nervous 6210664 4/3/01 system	1. Use of gallium to treat biofilm-associated infections	11700289	1/30/07
antitumor activity 4. Implantable polymeric device for sustained release of dopamine agonist 5. Implantable polymeric device for sustained release of nalmefene 6. Use of gallium to treat inflammatory arthritis 7. Use of pigmented retinal epithelial cells for creation of an immune privilege site 8. Methods of treating schizophrenia 8. Methods of treating schizophrenia 11497914 8/1/06 9. Treatment and prevention of adverse liver conditions using gallium 10. Implantable polymeric device for sustained release of buprenorphine 11. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst 12. Implantable polymeric device for sustained release of dopamine agonist 13. Method for gene transfer to the central nervous for system 14. Implantable polymeric device for sustained release of dopamine agonist 15. Implantable polymeric device for sustained release of dopamine agonist 16. Implantable polymeric device for sustained release of dopamine agonist 17. Implantable polymeric device for sustained release of dopamine agonist 18. Method for gene transfer to the central nervous for sustained device for sustained release of dopamine agonist		10453377	6/2/03
dopamine agonist 5. Implantable polymeric device for sustained release of nalmefene 6. Use of gallium to treat inflammatory arthritis 11015172 12/17/04 7. Use of pigmented retinal epithelial cells for creation of an immune privilege site 8. Methods of treating schizophrenia 11497914 8/1/06 9. Treatment and prevention of adverse liver conditions using gallium 10. Implantable polymeric device for sustained release of buprenorphine 11. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst 12. Implantable polymeric device for sustained release of dopamine agonist 13. Method for gene transfer to the central nervous system 6210664 4/3/01 system		10521548	8/22/05
nalmefene 6. Use of gallium to treat inflammatory arthritis 7. Use of pigmented retinal epithelial cells for creation of an immune privilege site 8. Methods of treating schizophrenia 8. Methods of treating schizophrenia 9. Treatment and prevention of adverse liver conditions using gallium 10. Implantable polymeric device for sustained release of buprenorphine 11. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst 12. Implantable polymeric device for sustained release of dopamine agonist 13. Method for gene transfer to the central nervous system 6210664 4/3/01		10815481	3/31/04
7. Use of pigmented retinal epithelial cells for creation of an immune privilege site 8. Methods of treating schizophrenia 11497914 8/1/06 9. Treatment and prevention of adverse liver conditions using gallium 10. Implantable polymeric device for sustained release of buprenorphine 11. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst 12. Implantable polymeric device for sustained release of dopamine agonist 13. Method for gene transfer to the central nervous system 6210664 4/3/01		10856178	5/27/04
8. Methods of treating schizophrenia 11497914 8/1/06 9. Treatment and prevention of adverse liver conditions using gallium 10. Implantable polymeric device for sustained release of buprenorphine 11. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst 12. Implantable polymeric device for sustained release of dopamine agonist 13. Method for gene transfer to the central nervous system 6210664 4/3/01	6. Use of gallium to treat inflammatory arthritis	11015172	12/17/04
9. Treatment and prevention of adverse liver conditions using gallium 10. Implantable polymeric device for sustained release of buprenorphine 11. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst 12. Implantable polymeric device for sustained release of dopamine agonist 13. Method for gene transfer to the central nervous system 14. Secondary 11. Secondary 12. Secondary		11363911	2/27/06
10. Implantable polymeric device for sustained release of buprenorphine 11. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst 12. Implantable polymeric device for sustained release of dopamine agonist 13. Method for gene transfer to the central nervous system 14. System 15. System 18. System 18. Method for gene transfer to the central nervous formula for sustained for sustained for system 18. S	8. Methods of treating schizophrenia	11497914	8/1/06
buprenorphine 11. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst 12. Implantable polymeric device for sustained release of dopamine agonist 13. Method for gene transfer to the central nervous 6210664 4/3/01 system	_	11594582	11/7/06
buprenorphine with minimal initial burst 12. Implantable polymeric device for sustained release of dopamine agonist 13. Method for gene transfer to the central nervous 6210664 4/3/01 system	<u> </u>	11801302	5/8/07
dopamine agonist 13. Method for gene transfer to the central nervous 6210664 4/3/01 system	• •	11805608	5/23/07
system		12119334	5/12/08
1 - 2		6210664	4/3/01
14. Methods of treating schizophrenia 7115256 10/3/06	- · · · · · · · · · · · · · · · · · · ·	7115256	10/3/06

-2-

TRADEMARK
REEL: 004516 FRAME: 0471

EXHIBIT B

Trademarks

Serial/ **Description** Registration No. File Date **SPHERAMINE** 75146837 8/8/96

WEST\223346337.1

RECORDED: 04/06/2011

TRADEMARK REEL: 004516 FRAME: 0472